Citius Pharmaceuticals Inc vs Endeavour Silver Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Endeavour Silver Corp trades at $10.9 (market cap $3.14B). The key difference: Endeavour Silver Corp is far larger — about 156.9× Citius Pharmaceuticals Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EXK | |
|---|---|---|
Market Cap | $20.01M | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $14.12 |
52-Week Low | $0.48 | $5.31 |
Enterprise Value | $16.23M | $3.14B |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
No Aura AI signal available yet.
Trailing returns across standard periods
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →